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Beneficial effects of breastfeeding are well-recognized and include both immediate
neonatal protection against pathogens and long-term protection against allergies and
autoimmune diseases. Although several proteins have been identified to have anti-viral
or anti-bacterial effects like secretory IgA or lactoferrin, the mechanisms of immune mod-
ulation are not fully understood. Recent studies identified important beneficial effects of
glycans in human milk, such as those expressed in oligosaccharides or on glycoproteins.
Glycans are recognized by the carbohydrate receptors C-type lectins on dendritic cell (DC)
and specific tissue macrophages, which exert important functions in immune modula-
tion and immune homeostasis. A well-characterized C-type lectin is dendritic cell-specific
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), which binds terminal
fucose.The present study shows that in human milk, MUC1 is the major milk glycoprotein
that binds to the lectin domain of DC-SIGN and prevents pathogen interaction through the
presence of Lewis x-type oligosaccharides. Surprisingly, this was specific for human milk,
as formula, bovine or camel milk did not show any presence of proteins that interacted
with DC-SIGN. The expression of DC-SIGN is found in young infants along the entire gas-
trointestinal tract. Our data thus suggest the importance of human milk glycoproteins for
blocking pathogen interaction to DC in young children. Moreover, a potential benefit of
human milk later in life in shaping the infants immune system through DC-SIGN cannot be
ruled out.
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INTRODUCTION
Inflammatory diseases like allergies and autoimmune diseases are
increasing in the Western world. These disorders are associated
with a disturbed immune balance, feeding the necessity to unravel
mechanisms of immune tolerance induction, specifically early in
life. For years, it is known that breastfeeding has beneficial effects
for infants at young age, for example, by strongly reducing the
mortality rate from infections by common pathogens. Moreover,
breastfed individuals showed, although with controversies, a lower
risk of developing allergies and autoimmune disorders such as
type 1 diabetes, Crohn’s disease, and juvenile rheumatoid arthritis
later in life (1–4). For a long time, protection against pathogens
was attributed to secretory IgA, which could capture pathogens
from the gastrointestinal system of the child. Later, also milk
components were identified as possible immune modulators. For
example, the major milk protein lactoferrin is well known for its
anti-viral and anti-bactericidal activity (5), and similar effects have
been described for lysozyme (6). Other immunologically inter-
esting components of human milk include growth hormones,
cytokines, and glycans.
Glycans in human milk are abundantly present in oligosaccha-
rides or on glycoproteins. These glycans may play an important
role in protective immunity in young children. It has been demon-
strated that the incidence of diarrhea caused by different pathogens
is inversely related to the type and amount of fucose-type gly-
cans in human milk that the infants received (7, 8). Interestingly,
high concentrations of such glycans were also significantly associ-
ated with a lower incidence of respiratory disease in children (9),
suggesting beneficial systemic effects as well.
Glycans are recognized by C-type lectins expressed mostly by
myeloid antigen presenting cells such as macrophages and den-
dritic cells (DCs). C-type lectins are carbohydrate receptors that
bind a variety of glycan moieties in a calcium-dependent man-
ner. They belong to the family of antigen uptake receptors, as they
recognize cell surface glycans on many viruses, bacteria, and par-
asites, but may bind and respond to glycans on self-proteins as
well. A well-characterized C-type lectin on DCs is dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin
(DC-SIGN). Ligands for DC-SIGN include fucosylated structures,
like the Lewis antigens, as well as mannosylated moieties. As
antigen uptake receptor, DC-SIGN shuttles antigen in the intra-
cellular compartments of DCs to load antigen on MHC class I
and II molecules to stimulate antigen-specific CD8 and CD4 T
cell responses, respectively (10–13). On the other hand, DC-SIGN
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recognizes a wide variety of pathogens that is not necessarily pre-
sented to T cells but rather modulates immune responses. For
example, DC-SIGN signaling following binding to Mycobacterium
tuberculosis, Borrelia burgdorferi, or HIV results in immune inhi-
bition through Raf-1 activation, prolonged Nf-κB activation, high
IL-10 production, or decreased expression of proinflammatory
cytokines (14–16). The diversity of DC-SIGN actions was fur-
ther shown by its ability to promote either Th1 or Th2 responses,
dependent on the phase variant of Helicobacter pylori (17). Also,
probiotics have been reported to interact with DC-SIGN, which
instead resulted in the induction of regulatory T cell responses
(18). In the case of a pathogen interacting with DC-SIGN, the
simultaneously triggering of specific toll-like receptors (TLR), and
the interplay between DC-SIGN and TLR signaling is important
in the differential outcome of the immune response. DC-SIGN
is thus an innate signaling receptor that dependent on the type
of glycan it interacts with (mannose or fucose) interferes with
TLR signaling (19). Based on its specificity for self-glycosylated
proteins, such as CEA, MUC1, MUC6, butyrophilin, DC-SIGN
has been considered important for maintenance of immune
homeostasis (20).
The contributions of the gastrointestinal tract in shaping
immunity are undeniable. Mucus layers, anti-bacterial proteins,
and numerous amounts of microbial communities, termed the
microbiota, all cooperate in protecting the host while provid-
ing metabolic benefits, as excellently reviewed by Hooper et al.
(21). Importantly, DCs are localized in all areas of the gastroin-
testinal tract. Equipped with C-type lectins and other molecules
for recognizing, internalizing, and presenting antigens, DCs are
the primary cells to initiate various immune responses, including
anergy. Despite all indications that abundant glycans in human
milk provide important benefits to the infant, underlying biologi-
cal mechanisms have not yet been addressed. Therefore, we aimed
to study the interaction of human milk with C-type lectins on DCs.
In adults, DC-SIGN is expressed on a subpopulation of DCs in the
intestinal mucosa (22, 23). However, information on DC-SIGN
expression in the gastrointestinal tract of neonates is scarce. Data
from the present study show that human milk strongly interacts
with DCs through DC-SIGN expressed in the entire gastrointesti-
nal tract of young infants. Furthermore, our data suggest that this
interaction is dependent on Lewis x present on the glycoprotein
mucin 1 (MUC1). We demonstrate this to be a potent mecha-
nism in blocking pathogen interaction with DCs and suggest this
to be an important mechanism of the capability of human milk
to modulate the infant’s immunity, presumably with long-term
health benefits.
MATERIALS AND METHODS
MILK SAMPLES
Human milk from 40 mothers was provided by the European
Milk Bank Association (EMBA, Milan, Italy). Human milk sam-
ples, as well as bovine milk (Campina, The Netherlands), formula
milk (Nutricia Nutrilon 1, Danone, reconstituted according to
the manufacturers instructions), and camel milk (camel farm
Smits, Berlicum, The Netherlands) were skimmed by obtaining
the aqueous phase after three consecutive rounds of centrifuga-
tion at 680× g for 10 min at 4°C. The samples were stored at
−80°C. For use in cell culture experiments, skimmed milk samples
were filter-sterilized. To fractionate human milk, the aqueous layer
(50 ml) was freeze-dried overnight and dissolved in 15 ml water,
mixed with 15 ml N-butanol and 30 ml di-isopropyl ether and
incubated at 4°C for 2 h, rolling. After centrifugation, the upper
(organic) layer was removed and aqueous layer mixed again with
30 ml di-isopropyl ether for 2 h incubation at 4°C. After centrifu-
gation, the aqueous layer was collected and freeze-dried overnight.
Twenty milliliters of PBS were added and proteins were solubilized
for 1 h by sonication and filtered through a 0.45µm filter. Finally,
milk proteins were separated on a gel filtration column [Sepharose
6 (10× 300), GE Healthcare Europe].
REAGENTS
Recombinant DC-SIGN and MGL proteins consisted of the extra-
cellular region (containing the carbohydrate recognition domain)
fused with an immunoglobulin Fc tail for detection in ELISA and
were produced by 293 T cells as described previously (24). The
DC-SIGN blocking antibody AZN-D1 and 1G6.6 antibody for
MGL were purified from hybridoma supernatant using a pro-
tein A sepharose FF column (Amersham). Lactoferrin isolated
from human milk was obtained from Sigma-Aldrich. MUC1 was
detected by clone 214D4 (provided by John Hilkens, Netherlands
Cancer Institute, Amsterdam) specifically recognizing the amino
acid sequence PDTR in the extracellular domain of MUC1 (glyco-
sylation independent) and was biotinylated using a biotinylation
kit (Pierce). MUC4 was detected by clone 8G7, κ-casein by clone
A-14 (Santa Cruz Biotechnology, Inc.), α-lactalbumin by clone
F20.16 (Novus Biologicals), Lewis x by clone P12 and Lewis y
by clone F3 (Calbiochem), CD83-PE by clone L307.4, CD86-PE
by clone 2331, HLA-DR-PE by clone L243 (BD Pharmingen),
and DC-SIGN by clone DC-28 (gift of R. Doms, University of
Pennsylvania, Philadelphia, PA, USA).
ELISA
Maxisorp ELISA plates (NUNC) were either coated directly with
skimmed milk or fractionated milk samples (in 1:10 dilution,
unless stated otherwise) in 0.2 M NaHCO3 buffer overnight at
4°C, or in case of human milk protein capturing ELISA, with puri-
fied lactoferrin (100 ng/ml) or with antibodies to MUC1 (unbi-
otinylated, 3µg/ml), MUC4 (40µg/ml), κ-casein (20µg/ml), or
α-lactalbumin (30µg/ml). The plates were blocked in Tris-sodium
buffer containing 1% BSA, followed by incubation with skimmed
human milk in case of milk protein capture. For C-type lectin
binding, plates were washed in Tris-sodium-0.05%Tween and
incubated with DC-SIGN-Fc or MGL-Fc for 1 h at room tem-
perature (RT). For MUC1 detection, plates were incubated with
biotinylated MUC1 antibody (2µg/ml). To detect Lewis-antigen
expression following MUC1 capture, plates were incubated with
antibodies to Lewis x or Lewis y (0.5µg/ml). After washing, bind-
ing of C-type lectins was detected by PO-labeled goat anti-human
IgG, binding of MUC1 by PO-labeled streptavidin and binding
of Lewis antigens by PO-labeled goat anti-mouse IgM (Jack-
son Immunoresearch). The reaction was visualized in 100µg/ml
3,3′-5,5′-tetramethylbenzidine (TMB) substrate (Sigma-Aldrich)
and optical density was measured by a microplate absorbance
spectrophotometer (Biorad) at 450 nm.
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CELLS
Human immature DCs were generated from monocytes isolated
from buffy coats of healthy donors (Sanquin, Amsterdam, The
Netherlands) by culturing the cells for 4–5 days in RPMI 1640
medium (Invitrogen) containing 10% fetal calf serum and in the
presence of IL-4 and GM-CSF (500 and 800 U/ml, respectively,
Biosource). Monocyte-derived DCs were matured in the presence
of LPS (10 ng/ml, Sigma-Aldrich) for 24 h and co-incubated with
sterilized human milk (1:10 dilution) and AZN-D1 (20µg/ml).
Next, cells were either washed and incubated with indicated anti-
bodies for detection in flow cytometry and analyzed using FlowJo
Software, or were used for quantitative PCR.
CELL ADHESION ASSAY
Nunc-Immuno Maxisorp plates were coated with milk (1:10 dilu-
tion unless stated otherwise) in NaHCO3 buffer (0.2 M) o/n at 4°C.
After washing and blocking the NUNC plate in TSM/BSA (1%),
DCs labeled with Calcein-AM (Molecular Probes) were added in
the presence or absence of the calcium chelator EGTA (10 mM),
AZN-D1 (20µg/ml), or 1G6.6 (20µg/ml) and incubated for
90 min at 37°C. The non-adherent cells were gently washed away
and the adherent cells were lysed in 50 mM Tris-HCL/0.1%SDS.
Fluorescence was quantified on a Fluostar spectrofluorimeter
(BMG Labtech) at 485/520 nm.
BACTERIA BLOCKING ASSAY
Dendritic cells (1× 105 cells/well) were incubated with filter-
sterilized milk (1:10 dilution), AZN-D1 (10µg/ml), 1g6.6
(10µg/ml), or Tris-sodium buffer alone for 45 min at 37°C. FITC-
labeled DC-SIGN binding variant of Neisseria gonorrhoeae (25)
or FITC-labeled H. pylori (phase variants J223.3 and J223.8) (17)
were co-incubated with the DCs in a 25:1 (bacteria:DC) ratio for
another 45 min at 4°C. Cells were washed in Tris-sodium buffer
and FITC-positive DCs were quantified using a flow cytometer
(Facscan, BD) and FlowJo Software (Tree Star, Inc.).
QUANTITATIVE PCR
Cells were lysed for RNA isolation (mRNA capture kit, Roche)
and cDNA synthesis (Reverse Transcription System, Promega),
according to manufacturers instructions, after which the cDNA
was stored in −20°C until further use. PCR reactions were per-
formed with the SYBR Green method in an ABI 7900HT sequence
detection system (Applied Biosystems,USA). Primer sets to the fol-
lowing human target genes were used: IL-10 (fw: 5′-gaggctacggc
gctgtcat-3′, rv: 5′-ccacggccttgctcttgtt-3′), TNF (fw: 5′-tctcgaaccc
cgagtgaca-3′, rv: 5′-tgaggtacaggccctctgatg-3′), IL-6 (fw: 5′-tgcaataa
ccacccctgacc-3′, rv: 5′-tgcgcagaatgagatgagttg-3′), IL-12p35 (fw:5′-
ccactccagacccaggaatgt-3′, rv: 5′-gcaggttttgggagtggtga-3′), and IL-
23p19 (fw: 5′-gcttgcaaaggatccacca-3′, rv: 5′-tccgatcctagcagcttct
ca-3′). Expression of the target gene was normalized to GAPDH
(fw: 5′-ccatgttcgtcatgggtgtg-3′, rv: 5′-ggtgctaagcagttggtggtg-3′),
based on a protocol for the definition of the optimal endogenous
reference gene (26).
IMMUNOHISTOCHEMISTRY
Paraffin embedded sections of stomach, duodenum, ileum, colon,
and rectum were derived from biopsies (taken for reasons such
as diarrhea, suspicion of celiac disease or Hirschsprung’s dis-
ease) or resections (of congenital malformations, such as atresia)
from three different infants per anatomical region. The aver-
age age was 6.5 months (range: 1 week–17 months). Material was
obtained with informed consent and has been approved by the Eth-
ical Committee VU University Medical Center (Amsterdam, The
Netherlands) Biobank Unit Pathology BUP2012-24. The absence
of tissue abnormalities was confirmed by a clinical pathologist
(JPvdV). Sections were deparaffinized and hydrated in a xylene to
alcohol to distilled water series, followed by heat-induced epitope
retrieval in sodium-citrate buffer (pH 7.6). Endogeneous peroxi-
dase was blocked in blocking buffer (DAKO EnVision). Sections
were incubated in 10% normal goat serum before incubating with
anti-DC-SIGN antibody (DC-28) for 1 h RT. Next, sections were
incubated with HRP-labeled secondary antibody (DAKO EnVi-
sion) and staining was visualized with DAB (DAKO EnVision).
Sections were counterstained with hematoxylin, dehydrated, and
mounted in Entallan. All washing steps between incubations were
performed in TSM/0.05%Tween.
STATISTICAL ANALYSIS
Data were analyzed for significance by one-way analysis of variance
and Spearman’s correlation test, using GraphPad Prism software
(version 5.01). Only p-values<0.05 were considered significant.
RESULTS
HUMANMILK BINDS DC-SIGN ON DCs
To establish the presence of DC-SIGN binding glycoproteins in
human milk, interaction of human milk with DCs was tested in
a cell adhesion assay. DCs strongly attached to coated human
milk, and to a lesser extent to coated bovine, camel, or formula
milk (Figure 1A). Because glycoproteins are abundantly present in
human milk, we hypothesized that binding is mediated by glycan
receptors, i.e., C-type lectins. Using Fc constructs, we indeed show
that human milk strongly interacted with DC-SIGN-Fc, but not to
MGL-Fc. In contrast, bovine, camel, and formula milk bound to
MGL-Fc,but not to DC-SIGN-Fc (Figure 1B). No differences in C-
type lectin binding were observed between unskimmed, skimmed,
and sterilized milk samples (data not shown). A cell adhesion assay
confirmed that the strong binding of human milk with DCs was
DC-SIGN dependent, because binding was completely blocked by
a DC-SIGN blocking antibody, whereas blocking MGL had no
effect (Figure 1C). These data show that human milk specifically
interacts with DCs via DC-SIGN.
LEWIS x ON MUC1 IN HUMANMILK BINDS DC-SIGN
Different milk proteins were tested for their ability to bind DC-
SIGN. Antibodies to the milk proteins mucin 1 (MUC1), MUC4,
α-lactalbumin, and κ-casein were coated on plates to capture the
proteins from human milk. Lactoferrin was used as purified pro-
tein. MUC1 was the only milk protein showing potent DC-SIGN
binding (Figure 2A). Next, human milk was fractionated into 30
fractions, based on protein size, after which we determined the
presence of MUC1 as well as the amount of DC-SIGN binding
in these fractions. A strong positive correlation between the level
of MUC1 and the capacity to bind DC-SIGN (r = 0.8, p< 0.0001,
Figure 2B) suggests that MUC1 is a major human milk component
binding to DC-SIGN.
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FIGURE 1 | (A) Binding of monocyte-derived dendritic cells to skimmed
human, formula, bovine, or camel milk. (B) Binding of skimmed milk to
DC-SIGN-Fc or MGL-Fc. (C) Binding of monocyte-derived dendritic cells to
skimmed human milk in different dilutions in the presence of EGTA, DC-SIGN
blocking antibody AZN-D1, or MGL blocking antibody 1G6.6.Three
independent experiments were performed. Data are indicated as mean±SD.
FIGURE 2 | (A) Binding of milk proteins to DC-SIGN. MUC1, MUC4,
κ-casein, and α-lactalbumin were captured from human milk using
antibodies, whereas lactoferrin was used in purified form. One
representative experiment out of three is presented. (B) Correlation of
MUC1 levels with DC-SIGN binding in fractionated human milk. Human
milk was fractionated into 30 fractions, based on protein size. MUC1 levels
and DC-SIGN binding was tested in ELISA. (C) Correlation of Lewis x levels
on MUC1 in 40 milk donors with the capacity of captured MUC1 binding to
DC-SIGN. (D) Correlation of Lewis y levels on MUC1 in 40 milk donors with
the capacity of captured MUC1 binding to DC-SIGN. Typical experiment out
of two is presented.
Next, we analyzed well-known ligands for DC-SIGN, Lewis x,
and Lewis y, on MUC1 in milk samples derived from 40 milk
donors. Both Lewis x and y could be detected on MUC1, but
expression levels are donor-dependent. Interestingly, levels of
Lewis x on MUC1 positively correlated with binding of MUC1
to DC-SIGN (r = 0.6, p< 0.0001, Figure 2C), but Lewis y levels
on MUC1 did not (r = 0.07, p= 0.69, Figure 2D). Importantly,
no correlation was found between the level of Lewis antigens and
the level of MUC1 in these samples (Lewis x: r = 0.27, p= 0.1;
Lewis y: r = 0.03, p= 0.8), indicating that higher MUC1 levels
do not inevitably contain higher Lewis antigen levels and thus
reflects individual variability in Lewis antigen expression. These
data therefore strongly suggest that human milk binds DC-SIGN
via Lewis x on MUC1.
INTERACTION OF HUMANMILK WITH DC-SIGN DOES NOT AFFECT DC
IMMUNE RESPONSES
DC-SIGN triggering has been described to modulate immune
responses (14). We therefore studied the effect of milk-DC-SIGN
interaction on DC-mediated responses. Although LPS activated
DCs incubated with human milk showed upregulation of IL-10
mRNA and protein levels, this was not attributed to DC-SIGN as
blocking DC-SIGN did not inhibit IL-10 induction (Figure 3A).
Similar results were obtained for TNF (data not shown). Human
milk did not affect the expression of IL-6, IL-12p35, and IL-
23p19 (data not shown). Furthermore, human milk did neither
induce DC maturation nor affected LPS-mediated DC maturation
(Figure 3B) or T cell proliferation (data not shown).
MUC1 IN HUMANMILK BLOCKS PATHOGEN INTERACTIONS WITH DCs
We hypothesized that the abundantly present glycoproteins
in human milk may have protective properties by preventing
pathogen interactions with DCs. To test this hypothesis, we incu-
bated DCs with the DC-SIGN binding variant of N. gonorrhoeae.
Binding of N. gonorrhoeae was inhibited in the presence of a
blocking DC-SIGN antibody, but not when MGL was blocked
(Figure 4A). Interestingly, human milk inhibited N. gonorrhoeae
binding to DCs to a similar extent as the DC-SIGN blocking anti-
body. As expected, formula milk, which does not bind to DC-SIGN
but rather binds MGL (Figure 1B), had no effect on bacteria bind-
ing. Because human milk binding to DC-SIGN is dependent on
Lewis x on MUC1 (Figure 2), we incubated DCs with N. gonor-
rhoeae in the presence of fractionated milk samples containing
different amounts of MUC1. Indeed, the fractions that inhibited
bacteria binding to DCs (Fraction C4, C6, and C8, Figure 4B),
showed strongest DC-SIGN binding in ELISA (Figure 4C), con-
tained highest levels of MUC1 (Figure 4D) as well as the highest
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FIGURE 3 | (A) IL-10 expression in human monocyte-derived dendritic cells
incubated in human milk with and without the blocking DC-SIGN antibody
AZN-D1. Expression is normalized to GAPDH. (B) Cell surface expression of the
maturation markers CD83, CD86, and HLA-DR on human monocyte-derived
dendritic cells following incubation with human milk and after LPS stimulation.
Data are indicated as mean±SD of three experiments performed.
amount of Lewis x present on MUC1 (Figure 4E), reflected in a
highly significant negative correlation between the percentage of
bacteria-positive cells and the levels of MUC1 (Figure 4F). To see
whether these observations also apply to a relevant gastrointesti-
nal pathogen, we tested the gastrointestinal pathogen H. pylori. We
used two phase variants of H. pylori that were previously shown
to bind differentially to DC-SIGN (17). We confirmed that phase
variant J223.3 binds to DC-SIGN but phase variant J223.8 does
not (Figure 4G), as a result of the lack of Lewis y and x (17). In a
competition assay, we further demonstrate that J223.3 binding to
DC-SIGN was inhibited by the negative controls mannan and the
calcium chelator EGTA and by human milk in a dose dependent
manner (Figure 4H). Like shown for N. gonorrhoeae, human milk
also blocks H. pylori J223.3 binding to DCs to a similar extent
as the DC-SIGN blocking antibody, and, in line with Figure 4A,
anti-MGL or formula milk did not affect bacteria binding to DCs
(Figure 4I). A strong and significant negative correlation between
J223.3-positive DCs and MUC1 levels demonstrates that MUC1
potently inhibits bacteria binding to DCs (Figure 4J).
DC-SIGN EXPRESSION IN INTESTINAL TRACT OF YOUNG INFANTS
To investigate the expression of DC-SIGN in the gastrointestinal
tract of young infants, we set out to stain various tissues obtained
from young infant. Irregular shaped DC-SIGN positive cells were
detected in the lamina propria of the stomach, duodenum, ileum,
and colon (Figure 5). Expression, however, was not uniform, with
each anatomical position containing areas with both high and low
numbers of DC-SIGN positive cells. In addition, strong DC-SIGN
expression was observed on cells in the submucosa of the ileum and
colon, like reported previously in adult tissue (22). The DC-SIGN
positive cells in the submucosa had an irregular shaped morphol-
ogy consistent with DCs, and some cells were in close vicinity of
blood vessels.
DISCUSSION
A wide spectrum of biologically active agents present in human
milk extensively promotes the development of the neonatal imma-
ture intestine and immune system. The beneficial effects include
maturation of the gut barrier, favorable colonization by probiotics,
development of tolerance, and thereby related protection against
allergies and autoimmune disorders later in life and immediate
protection against different pathogens early in life. In the present
study, we show how the heavily glycosylated protein MUC1 in
human milk prevents pathogen interaction via Lewis x interaction
with DC-SIGN, which is expressed on DCs throughout the gas-
trointestinal tract of young infants. Because C-type lectins are vital
in immune modulation and in the maintenance of immune home-
ostasis, these data provide further clues for potential mechanisms
for proper maturation and tolerization of the neonatal immune
system.
In the adult human gastrointestinal tract, DCs are located in
the submucosa and in the lamina propria, where they can form
protrusions to sample antigens from the gut lumen (27). Sev-
eral DC subsets with their own ontogeny have been identified
(22, 28), however, data on the presence and type of DCs in the
infants’ intestines are very scarce. Here, we identified DC-SIGN
expressing cells in the lamina propria of the stomach, duode-
num, ileum, colon, and rectum as well as in the submucosa of
the ileum, colon, and rectum of young infants. These data are
in line with DC-SIGN expression previously found in the lamina
propria and associated lymphoid aggregates in fetal tissue (29).
DC-SIGN, like most C-type lectins, act as antigen receptors that are
able to capture and internalize glycosylated self and foreign anti-
gens from the micro-environment. Although we did not observe
a direct DC-SIGN-mediated effect on DC cytokine production or
maturation in this study, DC-SIGN is considered important in
tolerance induction and maintenance of immune homeostasis by
modifying T cell responses (14, 20). Interestingly, mouse studies
demonstrate that antigen exposure via maternal milk prevents the
development of allergic asthma (30–32). Because of the presence
of DC-SIGN in the infant’s intestine and its immunomodulatory
capacity, we speculate an important role for DC-SIGN in captur-
ing antigens from human milk, thereby inducing tolerance. In fact,
it has been shown that the mouse homolog of DC-SIGN, SIGNR1,
conditions the mucosal immune system to reduce the anaphy-
lactic response triggered by food allergens (33). In addition, also
different species of probiotic lactobacilli drive the development of
regulatory T cells via specific DC-SIGN interaction (18). Conclu-
sively, these data support an important role for DC-SIGN in the
proper development of the neonatal immune system.
Whereas binding of antigens and probiotics in the intestine
is important for the induction of tolerance, human milk further
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FIGURE 4 | (A) Binding of N. gonorrhoeae to human monocyte-derived
dendritic cells in the presence of the DC-SIGN blocking antibody AZN-D1,
MGL blocking antibody 1g6.6, human milk or formula milk. Three independent
experiments were performed. (B) Binding of N. gonorrhoeae to
monocyte-derived dendritic cells in the presence of fractionated milk samples.
(Continued)
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FIGURE 4 | Continued
(C) DC-SIGN binding capacity of fractionated milk samples in ELISA.
(D) MUC1 levels in fractionated milk samples detected by ELISA.
(E) Lewis x expression on MUC1 captured from fractionated milk
samples in ELISA. (F) Correlation of MUC1 levels in fractionated milk
samples and the capacity of these samples to inhibit N. gonorrhoeae
binding to monocyte-derived dendritic cells. (G) Binding of phase
variants J223.3 and J223.8 from H. pylori to DC-SIGN-Fc in ELISA.
(H) Binding of H. pylori phase variants to DC-SIGN-Fc in the presence of
the calcium chelator EGTA, the DC-SIGN ligand mannan and human milk.
(I) Binding of H. pylori phase variant J223.3 to monocyte-derived
dendritic cells in the presence of anti- DC-SIGN or anti-MGL antibody,
human or formula milk. (J) Correlation of MUC1 levels in fractionated
milk samples and the capacity of these samples to inhibit H. pylori
J223.3 binding to monocyte-derived dendritic cells. Data are indicated as
mean±SD of three experiments performed.
FIGURE 5 | DC-SIGN expression in (A) stomach, (B) duodenum, (C,D) ileum, and (E,F) colon of young infants. Arrows indicate DC-SIGN positive cells in
the lamina propria and arrowheads point to positive cells in the submucosa. Nuclei are stained in blue. Magnification ×20.
protects the neonate by preventing interaction with pathogens like
Salmonella, Shigella, Vibrio cholerae, Escherichia coli, polioviruses,
rotavirus, and respiratory syncytial virus (RSV) (34). We here show
that MUC1 is a major milk protein preventing the interaction of
bacteria with DC-SIGN on DCs, via Lewis x, but not Lewis y moi-
eties. As this effect was observed for two different and unrelated
bacteria, it is highly likely that this mechanism applies to other DC-
SIGN binding bacteria as well. Importantly, in our earlier work, we
have demonstrated that fucosylated milk components, and in par-
ticular MUC1 interacted with DC-SIGN and was shown to inhibit
DC-mediated transfer of HIV-1 (35–37). In addition to MUC1,
also κ-casein inhibits adhesion of H. pylori to human gastric
mucosa (38), but our data indicate that κ-casein does not interact
with DC-SIGN. Indeed, inhibition of Streptococcus pneumoniae
and H. influenzae binding to airway epithelium byκ-casein seemed
rather to depend on GlcNAc containing saccharides (39). Other
milk proteins that via a diversity of mechanisms have demon-
strated potent protective effects include bile-salt-stimulated lipase
(BSSL) (40), soluble CD14 (41), immunoglobulins (42), lsyozyme
(6), and lactoferrin (5). Taken together, these milk proteins may
exert their protective effects alone, but it is more likely that they
act in synergy, where the current findings suggest MUC1–DC-
SIGN interaction as a significant mechanism in this system, via
Lewis-type antigens expressed on MUC1.
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The importance of glycans in human milk is stressed by stud-
ies showing strong inverse correlations between the incidence of
diarrhea caused by different pathogens such as Campylobacter,
Norovirus, and Calicivirus, and the levels and types of human
milk oligosaccharides (7, 8). In particular, 2-linked fucoses seemed
responsible for the protection. Although these studies focused
on oligosaccharides, our data indicate the importance of fucose
moieties on glycoproteins as MUC1 as well. Furthermore, we
corroborate an earlier extensive glycan analysis on human milk-
derived MUC1 revealing the presence of terminal fucoses (43).
Interestingly, such fucoses are not expressed in bovine milk (44),
confirming our data that bovine milk does not bind DC-SIGN,
and may therefore not have similar pathogen inhibitory mecha-
nisms as human milk. The high variability of fucoses in human
milk depends on the genetically determined FUT2 expression of
the mother. Failure to express this enzyme results in the inability to
attach 2-linked fucoses during the glycosylation process. Besides
inter-individual variability, secretion of the fucosylated glycans
also shows large variations during the course of lactation (40).
In addition to the relationship with diarrhea, it would be highly
interesting to study whether these individual variations affects
the development of the immune system and the immunological
outcome later in life.
At present, we have only begun to realize the importance of
our gastrointestinal tract in shaping the immune system. Under-
standing the immunological benefits of human milk compounds
is highly valuable in order to stimulate proper development of
the infant’s immune system. Additionally, infant formulas could
be supplemented with glycosylated compounds based on human
milk, aiming to provide the same beneficial effects. Most favor-
able, specific human milk compounds may be used to influence
the development of the infant’s immune system in such a way that
allergies and autoimmune diseases later in life will be reduced or
even eliminated.
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